MLTX MoonLake Immunotherapeutics
USHealthcareAs of 2026-08-24
Why MLTX matters now
MoonLake Immunotherapeutics (MLTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.37 with -2.47% on the session and $1.29B in market capitalization; recent performance reads 1-month +17.35% and YTD +45.75%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-69.7M, and EPS of $-0.98. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.9%.
The latest indexable market news headline is "MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $29.50; recent insider activity includes Bodenstedt Matthias filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.39
P/S
0.00
EV/EBITDA
-4.95
DCF Value
$4.08
FCF Yield
-15.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-85.6%
ROA
-64.2%
ROIC
-75.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-69.7M | $-0.98 |
| Q4 2025 | $0.00 | $-62.4M | $-0.93 |
| FY 2025 | $0.00 | $-227.3M | $-3.53 |
| Q3 2025 | $0.00 | $-69.7M | $-1.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$28.50
Target (Median)
$29.50
Target Range
$10.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CH
Exchange
—
Beta
1.04
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.